Nhwa's H1 profit rises 5.7% on fast-growing neurology drugs; pipeline and AI bets advance
First-half profit and revenue grew, led by neurology products Nhwa's first-half net profit rose 5.7% to 741 million yuan and revenue rose 6.9% to 3.218 billion yuan. Neurology product sales jumped 33.7%, the fastest-growing core segment, while anesthetics and psychiatric drugs also grew. Steady profit growth supports the share price.
The half-year results are the period's main hard financial news and show the core business still growing.
Cash flow and margins weakened even as profit rose Operating cash flow fell 43.3% to 280 million yuan, and gross margin slipped 1.38 points to 73.86%. Profit still grew, but weaker cash generation and margins are a real counterweight that can cap gains or make investors cautious.
It is the main negative in the results and gives a fair, balanced picture of the period.
New drug pipeline advances, including a new clinical approval Nhwa's Class 1 drug NH302 injection won clinical trial approval for treating acute pain. Its innovative drug NH600001 has been submitted for marketing approval, and schizophrenia drug NHL35700 entered Phase III. A richer pipeline raises hopes for future growth.
Pipeline progress is a key long-term value driver and includes a genuinely new approval this period.
AI mental-health unit raises 262 million yuan, diluting Nhwa slightly Investee Haoxinqing will raise 262 million yuan from seven new investors to fund AI psychological companion robots and digital mental-health tools. Nhwa waived its right to subscribe, so its stake falls from 19.10% to 18.04%, but it stays the largest shareholder.
It is the period's main corporate action and shows both an AI growth bet and mild dilution.